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ABSTRACT 
The potential usefulness of CA 15-3，TPA, and apolipoprotein(a) in 
diagnosis and monitoring of breast cancer patients was evaluated in 188 female 
patients with histologically confirmed breast cancer. Among them 60 have 
blood samples collected before surgery and about 2 weeks after surgery and 8 
have follow-up blood samples. Also recruited were 97 normal women and 15 
female patients with benign breast disease as controls. Plasma CA 15-3, TPA 
and apolipoprotein(a) were measured using MEIA, ELASA and RIA 
\ 
respectively. Both plasma CA 15-3 and TPA levels, not Apo(a), were shown 
elevated in breast cancer. The cut-off levels for CA 15-3 and TPA at 22U/ml 
and 1.40 ng/ml, respectively, gave 95% specificity, at this cut-off, the diagnosis 
sensitivity of CA 15-3 and TPA was 18% and 20% respectively. Using ROC 
analysis, selected cut-off value 15U/ml for CA 15-3 and 1,20 ng/ml for TPA, 
the sensitivity were 46% and 25% with specificity 78% and 89% respectively. 
Since there is no correlation between CA 15-3 and TPA, the combination use of 
both markers gave sensitivity and specificity of 53% and 75% respectively. The 
CA 15-3 and /or TPA are not useful for screening and diagnosis breast cancer 
due to its low sensitivity. The proportion and magnitude of changes in CA 15-3 
levels after surgical treatment were higher than that of TPA. In conjunction 
with other diagnostic tests, both markers in combination may be useful for 
diagnosis and monitoring of breast cancer. Their role in the follow-up and 
prognosis ofbreast cancer patients is a subject for further investigation. 
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摘要 
应用MEIA�ELASA和RL\的分析方法，对188例乳腺癌患者、 
15例良性乳腺病患者及97例正常对照者的血菜中CA 1 5 - 3 �T P A和 
八卩0(3)浓度进行研究。其中对60例乳腺癌患者作手术前后对比研究。 
结果：乳腺癌患者血菜中CA 15-3�TPA浓度显著升高，八?0浏无显 
著性差异。CA 15 -3�TPA断点分别取22U/ml�L40ng /ml ,特异度为 
95%，其灵敏度分别为18%�20%�应用ROC方法分析，CA 15-3： 15 
U / m l ,灵敏度4 6 % �特异度7 8 % ; TPA : 1.20 n g / m l ,灵敏度2 5 %特 
异度89%�由于〔八15-3和1?八无相关，联合应用其灵敏度和特异 
度分别为53%�75%�手术后血奖水平变化€八15-3大于了?八。结果 
表明：由于灵敏度偏低，血菜€八15-3和丁?八不适合单独用于蹄查及 
诊断乳腺癌。结合其它方法，可帮助诊断及监控乳腺癌。其在乳腺癌 
预后的作用有待进一步研究。 
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Chapter 1 Introduction 
1.1 Tumor Marker 
1.1.1 General concept of tumor markers 
Tumor marker can be defined as a substance present in or produced 
by a tumor or by the tumor's host in response to the tumor's presence 
that can be used to differentiate a tumor from normal tissue or to 
determine the presence of a tumor based on measurement in the blood 
or secretions. Such a substance can be found in cells, tissues, or body 
fluids. It can be measured qualitatively or quantitatively by chemical, 
immunological, or molecular biological methods to determine the 
presence of a cancer (Sell, 1992). 
It does not necessarily have to be tumor-specific, but may be a 
substance present in blood or urine or expressed at the cell surface in 
larger quantities by malignant cells or their environs than by their 
normal counterparts, and may thus represent a relative rather than an 
absolute marker of malignancy. Tumor markers that are produced 
within the tumor, whether by malignant or stromal cells, are said to be 
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tumor-derived, whereas those markers produced by non-malignant ceUs 
as a result of disturbance by the tumor are said to be tumor-associated. 
The first tumor marker discovered was the Bence-Jones protein 
(Bence-Jones, 1867). Since its discovery in 1847 by precipitation of a 
protein in acidified boiled urine, it has been a diagnostic test for 
multiple myeloma. The general application of tumor markers for 
monitoring cancer patients started until the discovery of a-fetoprotein 
(AFP) in 1963 (Abelev et al, 1963) and carcinoembryonic (CEA) in 
1965 (Gold et al, 1965). A brief history of the development of tumor 
marker research is shown in Table i-7. (Roulston et al，1993). 
1.1.2 Application of tumor markers 
(a). Screening for primary disease 
A tumor marker with excellent specificity and sensitivity may be 
use to diagnose primary disease before it is suspected clinically. Such a 
marker would significantly improve the chances of successfiil therapy, 
since the tumor could be treated at an early stage or before metastases 
have developed. 
(b). Diagnosis of primary disease 
A tumor marker could be used to establish the diagnosis of 
malignancy in a patient with symptoms, preferably in the early stages 
ofthe evolution of the tumor. 
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Table 1-1 Some milestones in tumor marker research 
Year Author(s) Contribution “ 
1846 Bence-jones Bence-jones protein 
1928 Brown Ectopic hormone syndrome 
1930 Zondek Human chorionic gonadotrophin 
(hCG) 
1932 Cushing Adrenocorticotropin (ACTH) 
1933 Gutmann & Gutmann Prostatic acid phosphatase (PAP) 
1949 Oh-Uti Deletion of blood group antigens 
1959 Market Isoenzymes 
1960 Newell Philadelphia chromosome 
1963 Abelev Alphafetoprotein (AFP) 
1965 Gold & Freeman Carcinoembryonic antigen (CEA) 
1969 Heubner & Todard Oncogenes 
1975 Kohler & Milstein Monoclonal antibodies 
1980 Cooper, Weinberg & Bishop Oncogene probes and transfection 
1985 Hams, Sager & Knudson Suppressor gene 
O^odified from J.E. Roulston, R.C.R Leonard: Serological Tumour Markers. 
1992,pp3-5) 
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(c). Prognosis oftreatment 
The tumor marker concentration at the time of diagnoses may be 
used to predict the likely clinical outcome. To be of value in prognosis, 
the tumor marker concentration should correlate closely with tumor 
size and / or activity, so that a modest elevation means a small localized 
tumor, whilst a greater elevation suggests buUcy disseminated 
malignancy or an aggressive tumor. 
(d). Monitoring of treatment 
The concentration of a particular tumor marker in a tumor marker 
positive patient may be used as a crude index of the size and^or activity 
of the tumor. The effectiveness of the therapy used to treat the tumor, 
whether it be surgery, chemotherapy, radiotherapy or a combination of 
these, may be monitored by measurement of appropriate tumor markers. 
Effective therapy to reduce the size /activity of the tumor will result in 
a corresponding fall in the plasma concentration of the tumor marker. 
(e). bidication of recurrence 
One of the most valuable functions of a tumor marker is to provide 
an early indication of tumor marker recurrence. Thus, there is a great 
merit in continuing to monitor a patient who was tumor marker positive, 
even after the concentration of that marker has stabilized, normalized 
or become undetectable following successful therapy. A further 
significant rise in the concentration of the tumor marker may provide 
the first evidence of recurrence and so allow for providence of 
recurrence and so allow for prompt and effective second line therapy. 
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1.1.3. Limitation of tumor markers 
An ideal marker should be: 
• stable and accurately measurable even in low concentrations 
• present in readily accessible samples，such as blood and urine 
• secreted exclusively by tumor cells o f a specific morphological type 
• quantitatively correlated with tumor burden and progress 
• measurable even when produced by a barely detectable tumor mass 
• differentiate benign and malignant or metastatic tumors. 
QAodifiedfrom C P Pang (1995) Tumor markers. Study Guide: 2-6) 
At the moment there is no tumor marker of proven value for early 
detection of breast cancer, no single marker of 100% sensitivity and 
specificity. There are some of prognostic indicating value and 
indication of recurrence but so far no single marker is absolutely 
satisfactory. An ideal tumor marker does not exit but there are tumor 
markers having established clinical value. AFP (a-Fetoprotein) is a 
marker for hepatocellular and germ cell (nonseminoma) carcinoma. 
(Taketa et al，1992). PSA (Prostate-Specific Antigen) is one ofthe most 
promising tumor markers. It is an organ-specific tumor marker, can be 
usedto early detection, staging and monitoring ofprostate cancer.(Chu, 
1992; Oesterling, 1991). 
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1.2 Breast Cancer 
1.2.1 Incidence in Hong Kong women 
Breast cancer has been recognized as a life-threatening disease 
since the time of the ancient Egyptians. Early reports of breast cancer 
can be traced to the 1930's (Baum M., 1982). Breast cancer is the most 
frequent type of cancer among women, accounting for approximately 
4% of all deaths, 20% of all cancer deaths, and 25% of all cases of 
cancer in Westem Europe and North American (Meden et al., 1995). 
In Hong Kong, breast cancer is now the second most common 
cancer and the second leading cause of cancer death in Hong Kong 
women. The annual incidence of breast cancer has increased to more 
than 1000 cases, which is three times more than the figure observed 30 
years ago. In 1991, there were 1133 new cases of lung cancer and 1106 
new cases of breast cancer in women. In the same year, 881 women 
died from lung cancer and 333 women died from breast cancer (1993 
Report, Department Health, Hong Kong Government). Table 1-2 
showed that approximately 50% of the breast cancer presented at an 
advanced stage in 1960s and 1970s. In the latter part ofthe 1980s, there 
were nearly 20% of the breast cancer present at an advanced stage and 
60% at stage H. (Cheung, l992)(Table 1-2) 
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Table 1-2 Staging at presentation in different time periods in Hong 
Kong. 
1966-75 1976-85 1986-90 
% % % 
In-situ cancer 0 0 2.1 
Stage I 6.1 6.1 14.9 
Stage n 42.0 47.8 62.4 
Stage m 45.7 37.8 19.6 
Stage IV 6.1 8.3 1.0 
QAodifiedfrom Polly S Y Cheung (1992) Breast cancer in Hong Kong- the needfor 
early detectionJHong Kong Med Assoc 4:248-252.) 
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1.2.2 Need for early diagnosis and prognosis 
Breast cancer affects about 7% of all women in the westem world 
and it is a leading cause of cancer mortality (Barak et al, 1990). The 
majority of patients with breast cancer will develop a recurrent and 
progressing disease (Harris et al, 1985) which requires systemic 
treatment to alleviate the symptoms or, occasionally, to prolong the 
patient's survival (Veach et al，1987). The number of fatal cases could 
be reduced by 90% with better early detection and treatment modalities 
(Schwartz et al, 1992). Current screening procedures include breast 
self -examination (BSE), mammography, and clinical examination. The 
mortality rate in women who participate in screening programs is 50% 
lower at 5 years than for women who have mot been screened (Shapiro 
et al, 1985). In part as a result of the high rate of morbidity associated 
with this cancer, a great deal of effort has been exerted to identify 
markers useful for early diagnosis and patient follow-up. However, it is 
a fact that the treatment outcome depends upon the tumor burden at the 
beginning of therapy: the smaller the tumor burden, the more effective 
the treatment. Atpresent, screening techniques such as chest X-ray, 
ultrasonography, bone scanning and skeletal surveys are of limited 
value in the detection of occult metastases. Unfortunately there are also 
no effective immunological or biochemical tests available to determine 
the presence of a small tumor mass. 
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1.3 Markers for Breast Cancer 
1.3.1 Usefulness of tumor marker for breast cancer. 
Breast cancer remains one of the most common lethal malignancies 
in the westem word. Of the epithelial malignancies, it is arguably the 
one for which tumor markers might have the greatest potential. For 
example, it is now clear from the results of well-performed randomized 
trials that screening and early treatment ofbreast cancer (including both 
primary and adjuvant systemic therapy) are superior to later treatment 
(Early 1992; Eddy 1989; Nystr6m et al., 1993). However, not all ofthe 
population stands to benefit from these maneuvers, and effective use of 
tumor markers might permit the application of screening and treatment 
more efficiently (Early 1992; Eddy et al., 1988; Fletcher et aL, 1992). 
Moreover, patients with established breast cancers may benefit from 
several different local and systemic therapies, each with various 
efficacies and toxicities (mastectomy, lumpectomy, radiation therapies, 
endocrine therapy, and chemotherapy).(Henderson et al.，1990) Tumor 
marker might permit selection of the most appropriate treatments for 
the individual patient based on her particular situation.fraAfe 1-3，1� . 
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Table 1-3 Potential utilities of tumor markers for breast cancer 
Setting Potential utilities ‘ 
Determine risk Germ line genes in normal tissue 
Screening Circulating antigens 
Genes and/or antigens in nipple aspirate, breast biopsy, 
fme needle aspirate 
Differential diagnosis Tissue markers ofhematologic vs. mesenchymal vs. 
epithelial organs 
Tissue markers of separate epithelial organs 
Circulating markers specific to separate epithelial 
organs 
Prognosis Genes or antigens in primary breast cancer tissue 
Genes or antigens in sccult, distant metastases 
Circulating antigens related to tumor burden or biology 
Prediction of response to: 
Endocrine therapy Estrogen receptor / Progesterone receptor 
Chemotherapy Tissue-based marker 
Novel therapies Tissue, circulating markers 
Prediction of impending Circulating antigens 
relapse 
Monitoring disease course Circulating markers 
QAodifiedfrom Daniel F. Hayes, Tumor markersfor breast cancer: Current 
utilities andfuture prospects. Hematology / Oncology Clinics ofNorth America. 
Vol 8. 3J994.) 
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Tablel4 Cancer markers that have been used for investigation of 
breast cancer. 
XJ XT ‘ Normal Sensitivity Specificity Name Nature Use* � 
Hrait % % 
D P M 
CEA(carcin 200 kDa 2.5-5.0 + ++ H~h+ 42-96 10-90 
oembryonic glycoprotein ^g/ml 
antigen 
TAG-72 Sialyl Tn 4-7U/ml ++ ++ 9—72 97 
CA 15-3 High mol wt 35 U/ml + ++ +++ 88—97 30~90 
glycoprotein 
CA 19-9 Sialyated 37 U/ml + ++ ++ 33—89 89—97 
Lewis XA 
CA 549 Glycoprotein 13U/ml + + ++ 78.1 97.4 
MCA 350kDa 11 U/ml + ++ +++ 20—80 84~94 
glycoprotein 
TPA Cytokeratins 85 U/ml + +++ 67—80 75 
8, 18and 19 
Cathepsm D cysteine + 4*+ 
proteases 
Sp2 Sp2 protein 14 U/ml 
Estrogen mtracelluIar 10,000/cell +++ + 
progesteron polypeptides 
e receptors receptors 
c-erbB-2 gene ++ +++ 
p53 tumor + +++ 
suppressor 
gene 
* P : Diagnosis; P: Prognosis; M: Monitoring) 
QAodified from: Serological Cancer Markers, Stewart Sell, Ed. Totowa, NJ, The 
Humana Press, 1992) 
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1.3.2 Some tumor markers for breast cancer. 
Carcinoembryonic Antigen 
Carcinoembryonic antigen (CEA) is a large family of related cell-
surface glycoproteins. The CEA family consists of about 10 genes 
located on chromosome 19. Up to 36 different glycoproteins have been 
identified in the CEA family. CEA is a glycoprotein with a molecular 
mass of 150 to 300 kD and contains 45 to 55% carbohydrate. It is a 
single polypeptide chain consisting of 641 amino acids, with lysine in 
the N-termmal CEA was originally introduced as a marker for colonic 
cancer (Gold et al, 1965) but it has later proved to be a universal 
marker for adenocarcinomas including breast cancer (Laurence et al, 
1972) 
Estrogen receptors and progesterone receptors. 
The estrogen receptors and progesterone receptors are intracellular 
receptors that are measured directly in tumor tissue. These receptors are 
polypeptides that bind their respective hormones, translocate to the 
nucleus,(Greene et al.,1984; Green et al.,1987) and induce specific 
gene expression. 
The estrogen receptor and progesterone receptor might be able to: 
(a) predict a response to specific therapies for metastatic disease: (b) 
predict the success of adjuvant hormonal therapy: and (c) assess the 
prognosis o fa specific tumor to metastasize. 
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c-erbB-2 
The c-erbB-2 (EDER-2/neu) gene encodes a transmembrane tyrosine 
kinase that is the receptor for a family of peptide hormones (Gullick， 
1990). Various methods have been used to measure c-erbB-2 gene and 
its product. These include direct measurement of gene amplification， 
mRNA level, and protein expression. 
Amplification of c-erbB-2 is found in breast, ovarian, and 
gastrointestinal tumors. Li breast cancer, it appears to be as useflil a 
prognostic indicator of overall survival as tumor size or estrogen and 
progesterone receptor expression but not as good as the number of 
lymph nodes involved in metastases (Slamon et al，1989) 
P53 
p53 is a tumor suppressor gene on the shore arm ofchromosome 17 
that encodes a protein that is important in the regulation ofcell division. 
The p53 gene product appears to regulate transcription of several other 
genes. There is evidence that the gene product is important in 
preventing the division of cells containing damaged DNA (Levine et al, 
1991;Finlay et al, 1989). 
p53 gene deletion is a frequent event along with other molecular 
abnormalities in colorectal carcinogenesis. Allelic deletions of p53 
occur in approximately 60% of human breast cancer (Prosser er al, 
1990). With immunohistochemistry, p53 expression is detectable in 
36% to 46% of clinical breast malignancies (Cattoretti et al, 1988; 
Ostrowski et al, 1991). p53 has also been associated with erbB-2 
positivity (Barbareschi et al，1992) In short-tenn follow-up , p53 shows 
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a trend toward poorer prognosis (Ostrowski et al, 1991) 
Cathepsin-D 
Cathepsin D, reported originally as a 52-kD proenzyme secreted 
form (Capony et al, 1982)，is an estrogen-induced lysosomal protease 
that is abnormally present in breast cancer cell.(Copony, et al, 1989) 
This proteolytic enzyme can react against basement membranes. 
Cathepsin-D also has mitogenic activity on MCF-7 cells that are 
estrogen depleted. Further studies showed that cathepsin-D was 
relatively low in resting mammary cells but was elevated in malignant 
and benign proliferative breast disease. These findings raised the 
suspicion that the cathepsin-D could both promote abnormal growth of 
cells as well as contribute to the metastatic potential of malignant cells 
through its disruption of the basement membrane and therefore might 
be a marker for a poor prognosis in breast cancer.(Tandon et al., 1990). 
Several studies have shown that high cathepsin D levels in extracts of 
tumor tissue are associated with poor prognosis. (Spyratos et al, 1989; 
Tandon et al, 1990; Thorpe et al，1989) 
CA 549 
Chemical characterization of this antigen has shown it to be a high 
molecular weight acidic glycoprotein. CA 549 can be separated into 
species with molecular masses of 400 and 512 kd. One monoclonal 
antibody, a murine IgGl termed BC4E 549, was raised by immunizing 
mice with partially purified membrane preparations from T417 human 
breast tumor cell line. The other antibody, BC4N 154 (a murine IgM), 
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was developed against human milk fat globule membranes (Bray et al, 
1987). CA 549 is not useful in detecting early breast cancer. CA 549 is 
better than CEA at identifying active breast cancer. Li the monitoring 
of advanced breast cancer patients, CA 549 correlates with disease 
progression and regression and helps detect metastases (Chan et al, 
1988). 
MCA 
MCA is referred to as mucinous carcinoma associated antigen. 
(Browning et al., 1988). MCA was identified on the surface of a breast 
carcinoma cell line by the monoclonal antibody b-12.11 is a marker for 
breast cancer (Bombardieri et al, 1992). Preliminary data show that 
level of MCA in sera correlate well with those of CA 15-3. MCA 
seems to be marginally superior to CA 15-3 in the follow-up of 
patients with breast cancer but again this remains to be confirmed 
(Browning et al., 1988) 
MSA 
MSA or mammary serum antigen is defined by reaction with the 
monoclonal antibody 3EI.2. (Stacker et aL, 1985). Preliminary data 
suggest that MSA may be a more sensitive marker for breast cancer 
tiian CA 15-3. There was study shown that MSA was elevated in 68% 
ofpatient with stage I and II breast cancer compared to only 3% for CA 
15-3(Sacks et aL 1987). These findings however, remain to be 
confirmed. 
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1.4 Selective Markers for Breast Cancer in This Study. 
1.4.1 TPA 
Tissue polypeptide antigen (TPA) was originally described by 
Bj6rklund and Bjorklund (1957). It was isolated from the insoluble 
residues of pooled tumors. Horse antiserum against the protein 
recognized both soluble form of TPA in human sera and body fluids, 
and an in soluble form in human tissues. Originally TPA was thought 
to be a tumor marker and, more recently, a proliferation marker 
(Bj6rklund, 1980). 
During the 1980's, a unique type of proteins, intermediate filaments, 
was discovered in epithelial cells. Intermediate filaments can be 
subdivided into five groups: cytokeratins, desmin, vimentin, GFAP 
(glial fibrillary acidic protein) and neurofilaments(Lazarides E 1982; 
Virtanen L et al, 1981). The cytokeratins, of which 20 have been 
isolated from different epithelial tissues, are further subdivided into 
type I (cytokeratins 9-19 and perhaps 20) and type H (cytokeratins 1-
8)(Lazarides, 1980; 1982; Moll et al, 1990;Steinart et al, 1985;Weber et 
al, 1984). It is now widely accepted that, for a normal formation of 
intermediate filaments two different cytokeratins are necessary, one 
type I and one type II, which form a pair. Cytokeratins appear in 
different combinations in different epithelial tissues and in each cell 
type，there is one or more cytokeratin pairs (Moll et al，1982; Quinlan 
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et al, 1985) 
Cytokeratins are multigene-coded and the different subtypes are 
related to the type of epithelial cell, and the extent of cell 
differentiation and development in the tissue. The genes for 
cytokeratins 8 and 18 are both found on chromosome 12(Waseem et al, 
1990a; 1990b). 
Cytokeratin expression remains throughout all stages of epithelial 
malignancy. The smallest cytokeratin pair, 8 and 18, is found in large 
quantities in simple, ductal and glandular epithelium, pseudo stratified 
epithelium, transitionsl epithelium and carcinomas arising therefrom 
(Moll et al, 1982; QuinIan et al，1985). Cytokeratins 8 and 18 have pI 
values of 6.1 and 5.7 respectively and molecular weights of 52kD and 
45 kD respectively. 
Cells in growing tumors and metastases release growth factors that 
stimulate endothelial cells in blood vessels to produce new blood 
vessels. The increased vascularization in the tumor results in further 
cell growth in parts of the tumor and an increased release of substances 
related to cell growth. This increased growth results in a blocking of 
blood vessels, cell death and cell lysis and release of proteolytic 
enzymes. 
Proteolysis of cell material releases a spectnmi of more or less 
degraded proteins, amongst them cytokeratins in their native form are 
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very insoluble and thus remain to a large extent in the necrotic regions 
of the tumor. There, along with the cell's intact cytokeratins，they can 
be visualized with immunohistological techniques. Solubilised 
fragments of cytokeratins can slowly leak out into the circulation. 
It can be postulated that cytokines endogenously produced as a 
result of cell division in growing tumors can affect epithelial cells. This 
could cause not only a restructuring of the cytoskeleton but also a 
significant release of cytokeratin fragments into the circulation. 
Serum cytokeratin fragment levels can be found in significantly 
higher concentrations in the serum of cancer patients than in normal 
individuals (Sundstrom et al, 1990). TPA (Tissue Polypeptide Antigen) 
has been described as a tumor associated antigen present in a variety of 
malignant tumors (Bjorkiund et al, 1957). Numerous clinical 
investigations have shown a high frequency of elevated levels of TPA 
in the serum of patients with tumor progression. An even higher 
frequency of elevated values is found among patients with distant 
metastases. 
A relationship between TPA and cytokeratins 8,18, and 19 has been 
demonstrated (Luning et al, 1983; Weber et al, 1984). Sequence 
identity between major fragments of TPA and cytokeratin 8 has been 
established as well as a high degree of homology (72%) between 
sequences of a TPA fragments and cytokeratin 18(Bahr et al, 1988; 
Leube et al, 1986; Redelius et al, 1980). It has been shown that 
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monoclonal antibodies against pertinent epitopes of cytokeratins 8,18 
and 19 can replace，individually or in pairs，the polyclonal TPA 
antibody used in the TPA JRMA kit (Mellereck et al, 1990). An 
increased concentration of cytokeratin fragments in serum correlates 
with tumor progression. 
In breast cancer, higher serum tissue polypeptide antigen levels 
were correlated with a poor prognosis (Gion^ et al; 1990). Conversely, 
a high cytosol tissue polypeptide antigen level was shown to be a 
powerfiil, independent, favorable prognostic indicator (Gion^ et al, 
1990;1993; 1994) 
However, recent work has shown that antibodies used in the tissue 
polypeptide antigen assay strongly react with cytokeratins 8 and 19, 
which tissue polypeptide specific antigen (TPS) antibody strongly 
reacts with cytokeratin 18, but very weakly with cytokeratin 8 in the 
immunoblot assay (Bodenmuller et al, 1994). 
1.4.2 CA15-3 
Cancer Antigen 15-3 
Monoclonal antibodies have recently been developed that detect 
circulating breast cancer associated antigen. CA15-3 assay values are 
defined by using the 115D8 and DF3 monoclonal antibodies.(Hayes DF, 
et al，1986; Tobias et al, 1985). 
The monoclonal antibody DF3, raised against a membrane enriched 
fraction of metastatic human breast carcinoma, react with epitopes 
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expressed by a family of high molecular weight glycoproteins 
designated as polymorphic epithelial mucinsOPEMs)( HiUcens^  et al， 
1984; HiUcens^ et al, 1984; Kufe et al, 1984; Taylor-Papadimitriou et al, 
1988). This antigen is a mucin-like glycoprotein with a highly variable 
molecular weight of300-450 kD (Sekine et al.,1985; Hayes et al.,1986). 
More recent research places the cause of its electrophoretic 
heterogeneity in the autosomal codominant expression of multiple 
alleles at one gene locus (Siddiqui et al., 1988). The gene for this 
molecule has been located on chromosome lq. cDNA cloning indicates 
that the DF3 peptide core consists of a highly conserved 60-bp tandem 
repeat sequence. The polymorphism of the antigen is the result of 
different repeats in the peptide core. The DF3 antibody recognizes the 
epitope within this 20 amino acid repeating sequence of the peptide 
core. The recognition of the epitope is also affected by 
glycation.(Hayes et al.,1992) Details ofbiochemical analyses suggest a 
relationship of the DF3 antigen with the sialyloligosaccharides 
(Ochuchi et al.,1984) by the presumed involvement of a terminal N-
^ acetyl-D-neuramic acid or a N-acetyl-glycosamine-residues on the 
development of the antigenic determinant (Sekine et al.,1985).The DF3 
antigen can be found on the surface and in the cytosol of human breast 
cancer cells. The immunoperoxidase technique shows this DF3 antigen 
primarily in the apical border region of benign secretory epithelial cells 
of the breast, whereas it was observed the accumulating in the cytosol 
of less differentiated, malignant cancer cells (Kufe et al., 1984). The 
technique also showed cytoplasmic staining in 78% of breast cancers 
and in 8% of fibroadenomal or fibrocystic disease specimens (Kufe et 
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aL, 1984; Lundi et aL, 1985). 
The second monoclonal antibody 115D8 raised against human 
milk-fat globule membranes (Hikens et al., 1984). It recognizes an 
antigenic determinant localized on the MAM-6 antigen, a very large 
glycoprotein of over 400 KD (Hikens et al., 1985). It has been shown, 
that many other malignancies, particularly tumors of the ovaries, the 
endometrium and the cervix,(Hikens et al.,1984) and some normal 
tissues like salivary and sweat glands,(Hageman er al., 1984) can 
produce large quantities of this antigen. 
Studies have demonstrated that monoclonal antibody DF3 and 
115D8 recognize distinct epitopes on the same antigen (Abe et al., 
1987). 
Research studies have indicated that CA 15-3 assay values are 
frequently elevated in patients with breast cancer.(Bon et al.,1990; 
Colomer et al.,1989; Dnistrian et al.,1991; Safi et al;1991;Silver et 
al.,1991;Tondini et al 1988). These studies have suggested that the CA 
15-3 assay may be of clinical value for monitoring the response of 
patients undergoing therapy because increasing and decreasing value 
correlated with disease progression and regression, respectively. 
(Robertson et al., 1990;Hayes et al 1986;Silver et aL, 1991). Additional 
published studies have suggested that increase CA 15-3 assay values in 
patients at risk for breast cancer recurrence after prime therapy may be 
indicative of recurrent disease before it can be detected clinically 
(Geraghty et aL, 1992; Safi et aL, 1991;HiDcens et al, 1986) 
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Elevations of CA 15-3 assay values have been reported in 
individuals with nonmalignant conditions such as cirrhosis, hepatitis, 
autoimmune disorkers and benign disease of the ovary and breast.(Bon 
et al.,1990;Colomer et al 1989). Non-mammary malignancies in which 
elevated CA 15-3 assay values have been reported include lung, colon, 
pancreatic, primary liver, ovarian, cervical and endometrial(Bon et al 
1990;Colomer 1989) CA15-3 assay values are not elevated in most 
normal individuals(Bon et al 1990). 
1.4.3 ApoUpoprotein(a) 
Lipoprotein(a) represents a family of lipoprotein particles varying 
in density between 1.05 and 1.10 g/ml and in size, owing to differences 
in protein-lipid ratio and protein composition. The protein moiety of 
Lp(a) consists of apolipoprotein B-lOO linked to apolipoprotein(a) by 
one or two disulfide bridges. It is slightly larger in size than LDL with 
a lipid composition similar to LDL, except for a relatively higher 
content of triglycerides (Scanu et al, 1991). 
Apolipoprotein(a), Apo(a), is a highly glycosylated protein linked 
by disulphide bridges to apolipoprotein B in the lipoprotein(a)(Lp(a)) 
particle and conferring the characteristic properties to the Lp(a) 
complex (Albers et al,1990). Apo(a) is formed by three different 
structural domains. One of the domains, caUed kringle 4, is present in 
multiple copies, the number of which varies and is genetically 
1 2 
determined, giving rise to different sizes of apo(a) and consequently 
Lp(a). Depending on the method used, six to 23 isoforms of apo(a) 
ranging from about 300 to 900 kD have been identified (Uterman et 
al,1989; Mbewu et al, 1990; Lackner et al, 1991; Kamboh et al, 
1991 ). Most individuals have one or two Apo(a) isoforais，although in 
some subjects no Apo(a) band can be detected when analyzed in SDS-
gel electrophoresis followed by immunoblotting (Albers et al, 1990). 
Up to the present time, much interest has been focused on Lp(a) 
since it has been associated with an increased risk of cardiovascular 
disease，and recently it was shown to be increased in various types of 
cancer (Wright et al,1989). Alterations in plasma lipoprotein 
metabolism are a well-documented phenomenon associated with tumor 
growth in both animals and humans (Barclay et al, 1975). In fact, 
individual lipoproteins have been suggested as potential markers of 
malignant disease (Skipski et al, 1975; Wieczorek et al, 1985; 
Mountford et al, 1987). There was an association between Lp(a) and 
malignant disease in acute myeloblastic leukemia (Niendorf et al，1992). 
This study was designed to investigate the association of Apo(a) with 
breast cancer and with the progression of the disease. 
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1.5 Objectives 
1.5.1 To evaluate the analytical performance of the three commercially 
available tumor markers: CA 15-3，TPA and Apolipoprotein (a). 
1.5.2 To study the potential clinical usefukiess of the three tumor 
markers in diagnosis and monitoring patients with breast cancer. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Patients and control subjects 
From April 1993 to October 1997, 188 patients with breast cancer 
and 15 benign breast disease patients attending the breast clinic of 
Department of Surgery, Prince of Wales Hospital, entered this study. 
Patients ‘ selection, based on clinical features and histopathological 
data, was carried out by clinical oncologists in the Department of 
clinical oncology, Princes of Wales Hospital. 97 healthy and disease-
free voluntary staffs of the Prince of Wales Hospital were recruited to 
serve as the control group. 
2.1.2 Sampling 
About 20ml moming fasting blood was obtained by venipuncture 
from each patient and healthy volunteer. For the cancer patients, pre-
operative blood collection was taken immediately after diagnosis，post-
operative samples was taken 10 days after surgery and before 
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treatments such as chemotherapy or radiotherapy. lOmL of blood was 
transferred into a EDTA tubes and the remaining lOmL into a plain 
tube. After centrifugation, the plasma and serum were aliquoted into 
1ml portions and stored at -70°C before analysis. 
2.2 Methods 
2.2.1 CA 15-3: Cancer Antigen 15-3 
The EVIx® CA 15-3 assay is a Microparticle Enzyme Immunoassay 
(MEIA) on JMx System for the quantitative measurement of CA 15-3 
in human semm and plasma.(Manufactured by Abbott laboratories, 
Diagnostics division, Abbott park, IL 60064, U.SA.) 
Dilution specimen and 115D8 antibody (mouse, monoclonal) 
coated Microparticles are added to the incubation well of the reaction 
cell. During the incubation of this reaction mixture, the 115D8 reactive 
determinant in the specimen binds to the monoclonal antibody 115D8 
coated Microparticles forming an antibody-antigen complex. An 
aliquot of the reaction mixture is transferred to the glass fiber matrix to 
which the microparticles are irreversibly bound. The matrix is washed 
to remove unbound materials. The DF3 antibody (mouse, 
monoclonal):AUcaline Phosphatase Conjugate is dispensed onto the 
matrix and binds to the antibody-antigen complex. The matrix is 
washed to remove unbound materials. And the substrate, 4-
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Methylumbelliferyl phosphate, is added to the matrix and the rate of 
fluorescent product formation is measured by the MEIA optical 
assembly. 
The CA15-3 antigen content OU/ml) is calculated using a standard 
curve generated by standard solutions provided in the kit. 
2.2.2 New TPA (Tissue Polypeptide Antigen) 
The EDeal Monoclonal TPA,yk ELASA is a test for the 
determination the key epitopes of TPA (Tissue Polypeptide Antigen) 
related to cytokeratins 8 and 18.(Manufactured by Mercodia AB, 
Seminariegatan 29, S-752 28 Uppsala, Sweden) Using BIO-RAD 
model 1575 immunowash and EL340 System microtiter plate reader 
adjusted for wavelength for 450nm. 
DDeal Monoclonal TPA y^^  ELASA is a solid phase sandwich assay. 
Specimens, standards and controls are incubated with a monoclonal 
anti-cytokeratin antibody mixture coated to wells, simultaneously with 
a HRP- labeled antibody. During the incubation, both the immobilised 
antibody and the HPR-labeled antibody bind to the cytokeratin 
fragments forming a sandwich. The wells are washed and a TMB 
substrate is added. The developed color is proportional to the 
concentration of the analyte. 
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Both the old polyclonal antibody-based tissue polypeptide antigen 
(TPA-P), which had been thoroughly studied in breast cancer，and the 
more recently available monoclonal antibody-based tissue polypeptide 
antigen (TPA-M) were used. Indeed，the latter tissue polypeptide 
antigen (TPA-M)assay presents two advantages in comparison to the 
old one: firstly，the cytokeratins recognized by the monoclonal 
antibody are well known, and secondly, the use of monoclonal 
antibodies should provide more reliable, stable and reproducible assay 
systems. 
EDeal Monoclonal TPA y^k differs from TPA-P by applying an assay 
with the monoclonal antibody instead of polyclonal antobodies as a 
tracer. According to Bj6rklund, TPA has nothing to do with 
cytokeratins and is, in contrary to new TPA, only related to cell 
proliferation. More recent findings, however, show that new TPA 
antibodies bind to keratin 8 and 18 positive tissue as well as to keratin 
negative tissues (Oehr et al., 1991) 
2.2.3 Apo (a): Apolipoprotein(a) 
Mercodia Apo(a) RIA provides a method for the quantitative 
measurement of human apolipoprotein(a)(Manufacture by Mercrodia 
AB, Seminariegatan 29 S-752 28 Uppsala, Sweden) using Auto-
Gamma® 5000 Series Gamma Counting Systems. 
Mercodia Apo(a) RL\ is a solid phase two-side innnunoradiometric 
assay. It is based on the direct sandwich technique in which two 
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monoclonal antibodies are directed against separate antigenic 
determinants on the apolipoprotein(a) molecule. During incubation 
apolipoprotein(a) in the sample reacts with 12 5-I-anti-apolipoprotein(a) 
antibodies and anti-apolipoprotein(a) antibodies bound to Sepharose® 
particles. The formed anti-antigen complex is separated firom excess 
tracer by addition of Decanting suspension followed by centrifugation 
and decanting. The radioactivity in the pellet is directly proportional to 
the concentration of apolipoprotein(a) in the sample. 
The kit is calibrated against a highly purified, fully validated, 
commercial Lp(a) preparation. The concentration of Apo(a) is 
expressed in U/L. It is not possible to express the concentration of 
Apo(a) in mass units as there are at least six different isoforms 
described with molecular weights varying from approximately 300 to 
900 kD(Uterman 1989; MBewu et al.,1990; Lackner et al.,1991; 
Kamboth et al.,1991). Thus each patient sample will contain different 
proportions of isoforms. Therefore no conversion factor can be given 
between Units of Apo(a) and milligrams of Apo(a). 
2.3 Statistical Methods 
The predictive value model has been applied by a number of 
investigators for evaluating the clinical performance and effectiveness 
of clinical laboratory tests. Sensitivity, specificity, predictive value and 
total accuracy define a laboratory test's diagnostic accuracy (Gail, 
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1979). Sensitivity indicates the frequency of positive test results in 
patients with a particular disease; specificity indicates the frequency of 
negative test results in patients without that disease. The predictive 
value of a positive test result indicates the frequency of diseased 
patients in all patients with positive test results. The predictive value of 
a negative test result indicates the frequency of nondiseased patients in 
all patients with negative test results. The total accuracy of a test 
indicates the percentage of patients correctly classified by the test. 
Sensitivity % = TP/(TP+FN)xlOO 
Specificity % = TN/(FP+TN) x 100 
Total accuracy % = (TN+TP)/(TN+TP+FP+FN)xlOO. 
Predictive value ofpositive test % = TP/(TP+FP)xlOO 
Predictive value ofnegative test %= TN/(TN+FN)xlOO 
TP, true positives: number of diseased patients correctly classified by the test; 
FP, false positives: number of nondiseases patients misclassified by the test; 
FN, false negatives: number of diseased patients misclassified by the test; 
TN, true negatives: number of nondiseased patients correctly classified by the test. 
Receiver operating characteristic (ROC) analysis was used to 
examine the clinical applicability of 3 biochemical markers for breast 
cancer. The use of ROC analysis has been suggested as an aid to 
clinical decision making (Hanley, 1989; Beck, et al., 1986). 
The statistical basis for ROC methods having been well described 
(Swets, 1988; McNeil, et al., 1984; Metz, et al., 1984). Briefly, when a 
test is used to detect patients having a disease，a critical test value is 
3 0 
usually selected that will best distinguish between the two groups. For 
tumor markers, results greater than the critical value (test positive) 
generally denote increased probability of disease. This system defines 
four groups, those are: test positive with the disease (true positive), test 
positive without the disease (false positive), test negative with the 
disease (false negative), and test negative without the disease (true 
negative). ROC analysis takes advantage of a simplification of these 
familiar categories. The entire population can be described by just two 
functions: true-positive fraction (the proportion of test positives among 
those with the disease) and false-positive fraction (the proportion of test 
positives among those without the disease). These fractions are linked 
by any given critical value. For tumor markers such as those discussed 
in this paper, selection of a higher critical value must result in a smaller 
false-positive fraction as well as a smaller true-positive fraction. 
Clearly, selection of a critical value can have a profound influence 
when tumor markers are compared. The simple expedient of plotting 
true-positive fraction against false-positive fraction for a range of assay 
values will overcome many of the difficulties inherent in analysis based 
on critical value. 
The difference between the marker levels in the different groups 
was calculated with the Mann-Whitney U test. The study for paired 
pre-operation and post-operation was calculated with the t-paired test. 
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Chapter 3 Results 
3.1 Precision studies 
3.1.1 CA 15-3 
The EMx® CA 15-3 MEIA kit was used to measure CA 15-3 on 
JMX. Litra-assay variation was estimated with controls containing low 
and high values of CA 15-3, the CVs were 2.4 % and 2.3% respectively, 
the interassay were 5.2% and 7.1% respctively (Table3-1). 
3.L2 TPA 
The E)eal Monoclonal TPA y^k ELASA kit was used to measure 
TPA. Intra-assay variation was estimated with controls containing low 
and high values of TPA, the CVs were 3.7 % and 4.4% respectively, 
the interassay were 3.8% and 2.3% respectively (Table 3-2), 
3.1.3 Apolipoprotein(a) 
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The Mercodia Apo(a) RJA were used to measure Apo(a). Latra-
assay variation was estimated with controls containing low and high 
values of Apo(a), the CVs were 5.7% and 3.1% respectively, the 
interassay were 5.0% and 2.8% respectively (Table 3-3). 
f' 
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Table 3-1 Intra- and inter-assay variation of CA 15-3 by MEIA on JMx 
System 
Assay value by Coefficient of variation 
Actual measured 
supply 
Mean(range) mean v ue Within assay Between Total 
(U/ml)* (U/ml)) % (n=10) assay assay % 
% (n=18) 
— 
35.4 2.4 4.6 5.2 
(23.6^3.8) 
CA 15-3 
150 
139.9 2.3 7.1 7.5 
(112.5—187.5) 
*EVk CA 15-3 Control Q<lo. 6A75-10) 
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Table 3-2 Intra- and inter-assay variation of TPA by ELISA on EL340 
Actual Coefficient of variation 
Assay value 
measured Within Between Total 
by supply * 
mean value assay % assay % assay % 
(ngAnl) 
(ng/ml) (n=15) (n=8) 
— ~ ~ 
1.66 3.7 3.8 5.3 
(0.91—1.91) 
TPA 
2.91 
3.45 4.4 2.3 5,0 
(2.16~4.00) 
TPAcky Control L and H (Lot No. KA9704). 
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Table 3-3 Intra- and inter-assay variation of Apo(a) by RIA on Auto-
Gamma® 5000 Series Gamma Counting Systems  
Assay Actual Coefficient of variation 
value by measuredd 
Within assay Between assay Total 
supply* mean value 
% (n=20) % (n=6) assay % 
{U/ml) (U/ml) 
— 
134 5.7 5.0 7.6 
(97—161) 
Apo (a) 
361 
376 3.1 2.8 4.2 
(275""458) 
Mercodia Apo(a) Control L and H ( Lot No. 1289), lyophilised Apo(a) 
concentration(Mean ±3S.D.). 
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3.2 CA 15-3 
3.2.1 CA 15-3 levels in healthy women, patients with benign breast 
disease and patients with breast cancer. 
The distribution of circulating CA 15-3 levels in normal subjects 
and patients with breast cancer were shown in FigJ-l. The frequency 
histogram shows a skewing toward increased CA 15-3 values. It can be 
seen that patients with breast cancer tend to have higher values of CA 
15-3, there is a great deal of overlap between the two groups� 
In 97 normal control subjects, the mean and median were 11.1±5.8 
U/ml and 9.1 U/ml respectively. CA 15-3 levels were >10 U/ml in 46 
subject (47.4%) and >15 U/ml in 22 (22.7%) subjects. Furthermore, 
only 8 (8.3%) of these subjects had CA 15-3 >20 U/ml and only 3 
(3.1%) of these subject had CA 15-3 levels >25 U/ml. In contrast, 188 
patients with breast cancer had a mean CA 15-3 level of 19.9士36.1 
U/ml and median 13.9 U/ml. 125 of these patients (66.6%) had CA 15-
3 levels >10 U/ml, 86 (45.9%) had CA 15-3 levels >15 U/ml, and there 
were 43 (23.0%) had CA 15-3 levels >20 U/ml and 23 (12.4%) had 
levels >25 U/ml. 
The median value, the 10-90% percentile range of CA 15-3 in groups 
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of normal contxols(median 9.1U/ml), patients with benign breast 
disease (median 9.8U/ml) and patients with breast cancer (median 
13.9U/ml) are shown in Figure 3-2. 
These data for patients with breast cancer are significantly different 
from those normal controls (p<0.001), patients with breast cancer had 
significantly higher CA 15-3 levels (median: 13.9 U/ml) than normal 
control (median: 9.1 U/ml) (Table 34’ Fig. 3-2). 
,-
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Fig, 3-1 Distribution of the plasma concentration of CA 15-3 in normal 
controls (n=97) and patients with breast cancer (n=188). 
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Table 3^ CA15-3 results 
Controls Benign Breast cancer 
i ; j ^ l5 l88 ' 
Mean 11.1 16.8 19.9 
Median 9.1 9.8 13.9 
SD 5.8 27.4 36.1 
Range 3.6-32.5 4.6-114.9 4.6-425.0 
~ ^ 0.0013 
Mann-Whitney U test to unpaired date Q)reast cancer vs controls) 
4 0 
�3 0 � 
S 25 L 
P 2 0 ^ 一 
f^  15 一 '• 
S 10 - • . 
^ 5 - , 
�0 --'^  -^^ '^^ ^^'" ^^  - ---^ -^ --^ ^^ ^ .: ' .. .....? .  •.....".... • 
Controls Benign Breast 
(n=97) (n=15) cancer 
(n=188) 
Figure 3-2 Comparison of CA 15-3 plasma levels in the three groups. 
(Horizontal bars, median value： thin vertical bar, 10-90^ percentile 
range.) 
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3.2.2 Sensitivity, specificity, and total accuracy of preoperative CA 
15-3 determination by cutoff value. 
The receiver operating characteristic (ROC) analysis of CA 15-3 as a 
discriminator between normal females and breast cancer patients is 
shown in Fig 3-3. The curve delineates the relationship between true-
and false-positive fraction for a range of critical marker values. 
,-
The sensitivity, specificity, and total accuracy were calculated using 
preoperative tumor markers of patients with breast cancer (n=188), 
with normal controls (n=97). We differentiated between the cutoff 
values of 10,15,20,and 22 U/ml. Comparing these results, sensitivity 
declined from 67% to 18% with an increase cutoff value. Specificity 
however improved from 53% to 78% and reach to 95%. This make the 
normal value of 15U/ml we selected and confirmed for health women 
appear the best choice, because both specificity and total accuracy are 
above 50%, with a sensitivity of46%. (Table 3-5) 
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ROC for CA15-3 
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Fig 3-3 Receiver-operator curve for data in CA 15-3. Breast cancer vs 
normal. 
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Table 3S Sensitivity, specificity, and total accuracy of CA 15-3 
determination 
CA 15-3~~~ “~~“ ‘ 
Sensitivity Specificity Total accuracy 
(UZml) (N=188) (N=97) (N=285) 
cutoff value 
Io ^ ^ ^ 
15 46 78 57 
20 23 93 47 
22 18 95 44 
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3.3 TPA 
3.3.1 TPA levels in healthy women, patients with benign breast 
disease and patients with breast cancer. 
The distribution of circulating TPA levels in normal subjects and 一 
patients with breast cancer were shown in Fig.34. The frequency 
histogram shows a skewing toward increased TPA values. It can be 
seen that patients with breast cancer tend to have higher values ofTPA, 
there is a great deal of overlap between the two groups. 
The distribution of circulating TPA levels in normal subjects and 
patients with breast cancer were shown in Fig.3-4. In 88 normal control 
subjects, the mean and median were 0.71±0.54 ng/ml and 0.58 ng/ml 
respectively. TPA levels were >0.4 ngAnl in 61 subject (69.1%), >0.8 
ng/ml in 30 (33.9%) subjects and >1.2 ngAnl in 10 (11.2%) subjects. 
Furthermore, only 4 (4.4%) of these subjects had TPA >1.4 ng/ml and 
only 3 (3.3%) of these subject had TPA levels >1.6 ng/ml. In contrast, 
115 patients with breast cancer had a mean TPA level of 1.23±3.39 
ng/ml and median 0.61 ng/mL 78 of these patients (67.7%) had TPA 
levels >0.4 ngAnl, 47 (40.8%) had TPA levels >0.8ng/ml, and there 
were 28 (24.3%) had TPA levels >1.2ng/ml, 23 (20.0%) had levels 
>1.4 ng/ml and 19(16.5%) han levels >1.6ng/ml. 
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The median value, the 10-90% percentile range of TPA in normal 
controls, patients with benign breast disease and patients with breast 
cancer are shown in Fig, 3-5, 
These data for patients with breast cancer are not significantly 
different from those normal controls (p=0.053), patients with breast 
cancer had higher TPA levels (median: 0.61ng/ml) than normal control 
(median: 0.58ng/ml) (Table 3-6，Fig. 3-5) ‘ 
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Distribution of TPA 
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Fig, 3-4 Distribution of the plasma concentration of TPA in normal 
controls (n=88) and patients with breast cancer (n=115) 
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Table 3-6 TPA results 
Controls Benign Breast cancer 
~N~~~~ ^ ^ H s " 
Mean 0.71 0.74 1.23 
Median 0.58 0.64 0.61 
SD 0.54 0.34 3,39 
Range 0.13-3.27 0.29-1.26 0.08-35.9 
~ ^ “ 0.0531 
* Mann-Whitney U test to unpaired date Qyreast cancer vs controls) 
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Figure 5-5 Comparison ofTPA plasma levels in three groups. 
(Horizontal bars, median value; thin vertical bar, 10-90'^'percentile 
range). 
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3.2.2 Sensitivity, specificity, and total accuracy of preoperative 
TPA determination by cutoff value. 
The relative operating characteristic (ROC) analysis of TPA as a 
discriminator between normal females and breast cancer patients is 
shown in Fig 3-6. The curve delineates the relationship between true-
and false-positive fraction for a range of critical marker values. -
The sensitivity, specificity, and total accuracy were calculated using 
preoperative tumor markers of patients with breast cancer (n=115), 
with normal controls (n=88). We differentiated between the cutoff 
values of0.50,1.00,1.20,and 1.40 ng/ml (Table 4-4). Comparing these 
results, sensitivity declined from 59% to20% with an increase cutoff 
value. Specificity, however improved from 44% to 89% an reach to 
95%. This make the normal value of 1.2ng/ml we selected and 
confirmed for health women appear the best choice, because both 
specificity and total accuracy are above 50%, with a sensitivity of25%. 
5 0 
ROC for TPA 
^ ....’？.,,一,...”.””〜.一:..、-…”,-.,..,v•-•-；-vv；；；•-v•^：;•：vr：-：.:：v•-;^; ：• — ••： ..-,...™...,-.,^  — -^ ^拿 
0.9 - ^ ^ i 
0.8 _^ ‘ 
J . 7 — ^/^•^"^^^ 
% 0.6 - ^ ^ 
•i 0.5 Mmrn.m 
I 0.4 _纖_::::^1|^麗::::::::, 
0-3 - ^ ^ 
0.2 -^||f^ ^^ ;::^ ^ 
0.1 J 
0 ^ -'' - '^ ' "-^ '^ '' "'"^'^‘^  .:. ‘ : . … “ ^ ‘ 
0 0.2 0.4 0.6 0.8 1 
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Fig. 3'6 Receiver operator curve for date in TPA. Breast cancer vs 
normal 
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Table 3-7 Sensitivity, specificity, and total accuracy ofTPA 
determination  
TPA (ng/ml) Sensitivity Specificity Total accuracy 
cutoff value (n=115) (n=88) (n=203) 
( ^ 1 ^ (%) 
0.50 59 44 52 
1.00 32 68 48 
1.20 25 89 53 
1.40 ^ ^ 53 
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3.4 Apolipoprotein (a) 
3.4.1 Apo(a) levels in healthy women, patients with benign breast 
disease and patients with breast cancer. 
The distribution of circulating Apo(a) levels in normal subjects and 
patients with breast cancer were shown in FigJ-7. The frequency 
histogram shows a skewing toward increased Apo(a) values. It can be 
seen that patients with breast cancer tend to have higher values of 
Apo(a), there is a great deal of overlap between the two groups. 
The distribution of circulating Apo(a) levels in normal subjects and 
patients with breast cancer were shown in Fig, 4-7. In 97 normal 
control subjects, the mean and median were 251.4±326.7 U/L and 
137.5 U/L respectively. Apo(a) levels were >lOOU>/L in 58 subject 
(60.5%), >200U/L in 39 (40.9%) subjects and >400U/L in 19 (19.6%) 
subjects. Furthermore, only 8 (8.2%) of these subjects had Apo(a) 
>600U/L and only 3 (3.0%) of these subject had Apo(a) levels >800 
U/L.In contrast, 188 patients with breast cancer had a mean Apo(a) 
level of231.8+220.3 U/L and median 137.2 \jrL. 125 of these patients 
(66.6%) had Apo(a) levels >100 U/L, 75 (40.0%) had Apo(a) levels 
>200U/L, and there were 37 (19.7%) had Apo(a) levels >400 U/L, 16 
(8.5%) had levels >600 U/L and 3(1.6%) had levels >800 u/L 
The median value, 10-90^^  percentile range of Apolipoprotein(a) in 
groups of normal controls, patients with benign breast disease and 
1 3 
patients with breast cancer are shown in Figure 3-8 
These data for patients with breast cancer are no significantly 
different from those normal controls (p=0.2978), patients with breast , 
cancer had equal Apo(a) levels (median: 137.2 U/L) with normal 
control (median: 137.5 U/L) (Table 3-8，Fig. 3-8). 
The relative operating characteristic (ROC) analysis of Apo(a) as a 
discriminator between normal females and breast cancer patients is 
shown in Fig 3-9, The curve delineates the relationship between true-
and false-positive fraction for a range of critical marker values. 
There are no assignment of cut off value if needed because there is no 
association of Apo(a) to breast cancer. 
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FigJ-7 Distribution of plasma Apo(a) in normal controls (n=97) and 
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Table 3-8 Apo(a) results    
Controls Benign Breast cancer 
i r ^ f5 1^ 
Mean 251.4 177.4 231.8 
Median 137.5 147.0 137.2 
SD 326.7 112.8 220.3 
Range 4.8-2635.1 15.6-410.9 1.1-1050.0 
^ ~ 0.2978 
Mann-Whitney U test to unpaired date (breast cancer vs controls) 
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Figure 3-8 Comparison of Apolipoprotein(a) plasma levels in three 
groups. 
(Horizontal bars, median value; thin vertical bar, 10-90出 percentile 
range.) 
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Fig 3-9 Receiver operator curve for Apo(a), Breast cancer vs normal 
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3.5 Combination test 
一-
Disease group comparisons were made using line regression analysis in 
which all three markers were used as variables to examine the 
predictive values of using multiple markers as opposed to any single 
marker. (Fig 3-10,Fig 3-ll,Fig 3-12) 
Combination Testing 
Using cutoff 15U/ml for CA 15-3 and 1.2 ng/ml for TPA, values 
were calculated with date from patients with breast cancer (n=l 15) and 
compared with patients with breast disease plus healthy female controls 
(n=103). Predictive value of positive test = % of patients with positive 
test results who are diseased. 
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Fig. 3-10. Correlation between TPA and CA 15-3 in pre-operative 
breast cancer patients fN=l 15) 
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Fig.3-ll Correlation between CA 15-3 and Apo(a) in pre-operative 
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Fig.3-12 Correlation between TPA and Apo(a) in pre-operative breast 
cancer patients (n=l 15). 
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Table 3-9 CA15-3 and TPA in breast cancer ‘ 
Marker Sensitivity Specificity Positive Negative 
predictive predictive 
CA-15-3 52(45%) 83(81%) ^ ^ 
TPA 28(24%) 92(89%) 72% 51% 
CA15-3 and TPA 19(17%) 98(95%) 19% 51% 
CA 15-3 or TPA 61(53%) 77(75%) 70% 59% 
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3.6 Study in pairs 
3.6.1 Results of the pairs investigation 
The CA 15-3, TPA and Apo(a) plasma levels were measured before 
and after operation. Pre- and post-operation samples from 60 clinical 
courses of patients with breast cancer were evaluated with the CA 15-3 
assay and Apo(a), 55 patients were evaluated with the TPA assay. The 
CA 15-3 levels ofpost-operation (mean±SD, 13.2±6.2) was significant 
lower than pre-operation (mean±SD, 18.3±18.5) (p<0.01). The TPA 
levels of post-operation (mean±SD, 0.82±0.85) was weakly significant 
lower than pre-operation (mean±SD, 0.97±1.01) (p<0.05). The Apo(a) 
levels of post-operation (mean±SD, 232.7±196.5) was not significant 
with the pre-operation (mean±SD, 237.3+209.6) (p-0.3687).(raAfe 3-7) 
3.6.2 Changes in post-operation compared with the pre-operation 
levels 
The CA 15-3, TPA and Apo(a) levels change in surgery were compared 
with the pre-operation level. Percent change in these markers were 
calculated as: 
CA 15-3_-CA 15-3„^ … 
% change 15-3= 二 ； ^ ^ ~ ~ xlOO 
L/A D_jpre 
% Change TPA= 巧：：吓‘ x 100 
lP ^ re 
1 4 
%changeApo(a)= ， ( 仏 丨 ？ ， . 勘 
in which markerp,e represents the level of pre-operation and markerp^st 
represents the level of post-operation. 
CA 15-3 levels decreased by at least 10% of the pre-operation level in 
40 of 60 patients (66.7%) with surgery. Furthermore, CA 15-3 levels 
decreased by at least 20% in 27 of these 60 patients after operation. For 
TPA, there was 30 patients (54.6%) decrease by at least 10% and 21 ‘ 
patients (36.3%) increased by at least 10% after operation. {Fig, 3-13; 
Table 3-8) 
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Table 3-10 The pre- and post-operation results of CA 15-3, Apo(a) and 
TPA.  
CA15-3 Apo (a) TPA 
Pre- Post- pre- Post- Pre- Post-
operation operation operation operation operation operation 
N 60 60 60 60 55 55 
Mean i ^ 13.2 237.3 232.7 0.97 0.82 
Median 14.3 11.6 158.7 174.3 0.61 0.59 
^ 18.5 6.2 209.6 196.5 1.01 0.85 
Range 5.5—115.4 5.4—38.0 10.1--1050.2 9.8—930.3 0.17—5.65 0.114.20 
" ^ 0.0018 0.3687 0.0412 
* t-paired test 
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Fig. 3-13 Changes in CA 15-3, TPA and Apo(a) levels after operation. 
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Table 3-11 The initial changes in the three markers levels after 
operation. 
biitial changes in markers after operation 
Decrease — increase 
Variation±10% 
>20% >10% >10% >20% 
CA 15-3 (n=60) 27(45%) 13(21.7%) 16(26.7) 3(5%) 1(1-6%) 
TPA (n=55) 27(49.1%) 3(5.5%) 5(9.1%) 2(3.6%) 18(32.7%) 
Apo(a)(n=60) 15(25%) 2(3.3%) 13(21.7%) 6(10%) 24(40%) 
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Chapter 4 Discussion 
Breast cancer is the second most cancer and the second leading 
cause of mortality among women in Hong Kong (Dept. of Health 
Report, 1993). Early detection will enable prompt treatment and reduce 
mortality and morbidity. However, in primary breast cancer the 
‘classic，tumor markers, carcinoembryonic antigen (CEA) (De Jong-
Bakker, et al., 1981) and tissue polypeptide antigen (TPA) (Bates et al., 
1985), are neither sensitive nor specific enough to indicate the spread 
of the disease and its clinical course. Monoclonal antibodies (Mab) 
techniques are more sensitive and specific than previous assays. CA 15-
3 uses 115D8 and DF3 (Hayes et al., 1986) and new TPA uses 
monoclonal antibodies relative to cytokeratins 8 and 18. We examined 
the relative merits of measuring CA 15-3, TPA and Apolipoprotein(a) 
levels in the detection and monitoring ofbreast cancer. 
The level used as the upper limit of normal has differed in various 
reports. Although some variation exits between laboratories, the 
mean±SD ofCA 15-3 level in normal subject ranges from 7 to 18 士 3-9 
U/ml (Colomer et al., 1986; Hayes et al., 1986; Sacks et al., 1987) 
These data have been used to determine the appropriate cut-off that 
distinguishes normal subjects from patients with breast cancer. The 
choice of cut-off level is important for evaluation of the efficacy of the 
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tumor maker. The situation is complicated by the fact that no 
standardization of the assays has been made. Different result has been 
obtained by assays from various manufactures. Some workers 
(Colomer et aL, 1986; Sacks et al., 1987)) used an upper limit of nomal 
of 40 U/ml while others used 25 U/ml (Pons-Anicet et al., 1987). In 
our study, the mean±SD ofCA 15-3 level in normal subject were 11.1± 
5.8, selected cutoffvalues of 22 U/ml, below which 95% of the normal 
population will fall. At this cutoff, the sensitivity for breast cancer was 
18%. The cut-off values to use are controversial since sensitivity and 
specificity depend the cut-off. There were study plotted receiver 
operating characteristics (ROC) curves for CA 15-3(Eskelinen et al., 
1989; Hayes et al., 1986; Pons-Anicet et al., 1987). In this study, using 
ROC, selected cutoff at 15 U/ml, the sensitivity and specificity were 
46% and 78% respectively. 
In one study , the cut-off level (95% specificity) was 30U/ml for CA 
15-3, the diagnostic sensitivity was 32% for the detection of breast 
cancer.(Giai et al, 1996) CA 15-3 basal levels were solely related to 
tumor size and nodal involvement. The CA 15-3 1evels appear to be 
independent of histology estrogen receptor content, or histologic grade 
ofthe primary tumors, but are related to the stage and extent of disease 
(Hayes et al., 1986; Colomer et al., 1989; Safi et al., 1989). There were 
study indicated that CA 15-3 were insufficiently sensitive and specific 
to be used to screen the general population (Tondini, et al., 1989). 
hi this study. The K)eal Monoclonal TPA.y^ELASA is a test for the 
determination the key epitopes of TPA (Tissue Polypeptide Antigen) 
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related to cytokeratins 8 and 18, the monoclonal antibody appeared to 
detect more specific epitope. Jn our study, at the cutoff l.4 ngy^ ml, the 
sensitivity and specificity were 20% and 95% respectively. Using ROC 
analysis, selected cutoff 1.2ngAnl, the sensitivity and specificity were 
25% and 89% respectively. Using cutoff 15 U/ml for CA 15-3 and 1.2 
ng/ml for TPA, the false-positive rates for CA 15-3 and TPA in normal 
subject were 19% and 11%, respectively. Another study shown that the 
false -positive rate were 16% and 4%.(Barak etal.,1990). In one study, ‘ 
the cut-off levels (90% specificity) the diagnosis sensitivity of the TPA 
test was 23% and 13% for the CA 15-3 test. When the cut-off were 
determined at 95^ ^ percentile level, the diagnostic sensitivity of the TPA 
and CA 15-3 were 12% and 6% respectively (Eskelinen et al, 1994). 
The mean and median levels of CA 15-3 and TPA in patients with 
breast cancer were significantly higher than those of normal controls. 
Our study demonstrated that CA 15-3 was more sensitive than TPA. 
TPA, has been regard as a risk factor rather than a real tumor marker 
fNicolini er al., 1989), However, in our study TPA at selected cut off 
levels showed a good specificity. Correlation was not found between 
TPA and CA 15-3，so the use of CA 15-3 together with TPA increases 
the sensitivity. The combined sensitivity of CA 15-3 and TPA 
increased to 53%, but the main problem with CA 15-3/ TPA stems 
firom their low combined specificity (also found by Eskelinen et al., 
1989) of 75%, while their individual specificity was 83% for CA 15-3 
and 92% for TPA. 
Jn our study indicates that CA 15-3 and TPA had limited value in 
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breast cancer diagnosis, the combined use of tumor markers in breast 
cancer diagnosis may have some clinical value, so far such test have 
too low a specificity to be of practical value in screening. 
Human mammary tissue metabolizes lipids from plasma, a process 
affected by female gonadal hormones. Both benign and malignant 
proliferation of breast tissue in women has associated with changes in 
plasma lipid and lipoprotein levels. The ratio of apolipoprotein A-I to 
serum Apolipoprotein B levels at time ofbiopsy has been referred to be 
the best predictor of cancer recurrence.(Lane DM et al, 1995). Breast 
cancer was proved to be associated with increased lipoprotein(a) 
(Alexopoulos et al, 1987). 
In our study, the plasma levels of Apolipoprotein (a) in the breast 
cancer patients group not differed significantly from normal controls 
(p=0.2978). The variation of Apo(a) in our study could be attributed to 
other causes, such as smoking, alcohol consumption, atherosclerotic 
vascular disease, hypertension, diabetes mellitus, or hyperlipidemia. 
The clinical application of circulating tumor markers remains a 
controversial subject in terms of useful methods and correct 
interpretation of findings. In particular and despite numerous 
investigations in the field, we do not have highly specific and sensitive 
biological markers in breast cancer. Nevertheless, many researchers 
often utilize circulating tumor markers in various phases of this 
malignancy to obtain additional information about disease extent and 
clinical course. 
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Chapter 5 Conclusions 
1. The is an association between CA 15-3 and occurrence of 
breast cancer. 
2. There is an association between new TPA and occurrence of 
breast cancer. 
3. Apolipoprotein(a) is not associated with breast cancer. 
4 CA 15-3 and TPA in combination improve specificity. 
5. CA 15-3 andAn" TPA are not useful for screening, in conjunction 
with other diagnostic tests, both markers may be useful for 
diagnosis & monitoring ofbreast cancer. 
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